Ropeginterferon Alfa-2b Gains ET Approvals Across Major Global Markets, Broadening Treatment Access for Patients PharmaEssentia Corporation’s blood cancer treatment, ropeginterferon alfa-2b (Ropeg), is expanding its presence in the global market following regulatory approvals for essential thrombocythemia (ET) in Taiwan, Japan,…
Avanzanite Bioscience Expands UK Operations, Appoints Sarah O’Connell as Country Manager to Strengthen Rare Disease Medicine Access Avanzanite Bioscience B.V., a European pharmaceutical company specializing in rare diseases, has announced the expansion of its United Kingdom (UK) operations and the…
Powerful Medical Secures New CPT Code for Queen of Hearts AI ECG Technology to Detect Heart Attacks Powerful Medical, a company specializing in artificial intelligence (AI)-driven cardiovascular diagnostics, has announced that the American Medical Association (AMA) CPT® Editorial Panel has…
HeartBeam’s 3D ECG Technology Accepted into FDA’s TAP Program to Advance Heart Attack Assessment HeartBeam, Inc., a medical technology company focused on transforming cardiac care through advanced cardiac insights, announced that the U.S. Food and Drug Administration (FDA) has accepted…
Edwards Lifesciences Receives FDA Approval for PASCAL Precision System for Tricuspid Valve Repair Edwards Lifesciences Corporation (NYSE: EW), a global developer of patient-focused innovations for structural heart disease, has announced that the U.S. Food and Drug Administration (FDA) has approved…
Cosette Pharmaceuticals Receives FDA Approval for EVOXAC® Oral Solution to Treat Dry Mouth in Adults With Sjögren’s Disease Cosette Pharmaceuticals, Inc., a U.S.-based specialty pharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has approved EVOXAC® (cevimeline…
Proteintech Appoints Patrick Yount as CFO and Promotes Jeb Gaybrick to Lead Corporate Strategy and Investor Relations Proteintech Group, Inc., a global life sciences company, has announced two leadership changes aimed at supporting its continued growth and preparing the organization…
Bausch + Lomb Appoints Thomas J. Appio as Interim CEO as Brent Saunders Departs Bausch + Lomb Corporation, a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC), have announced the appointment of Thomas…
Genentech’s Tecentriq Receives FDA Approval for Adjuvant Treatment of Stage III dMMR Colon Cancer Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and…
FDA Approves Pfizer’s TUKYSA Regimen for First-Line Maintenance in HER2+ Metastatic Breast Cancer Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults…
City of Hope Names Laurie Sicaeros and Melissa Childress to Lead Cancer Centers in Arizona and Atlanta City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, has appointed two experienced…
Shape Memory Medical Receives ANVISA Authorization for IMPEDE Embolization Plug Portfolio in Brazil Shape Memory Medical Inc., a medical technology company developing volume-expanding shape memory polymer solutions for endovascular embolization, has announced that Brazil’s national health surveillance agency, Agência Nacional…